Welcome to our dedicated page for AI / ML Innovations news (Ticker: AIMLF), a resource for investors and traders seeking the latest updates and insights on AI / ML Innovations stock.
AI/ML Innovations Inc. develops artificial intelligence and neural-network technology for digital health applications. The company’s platforms use signal processing and deep learning to convert biometric data into clinical insights, with recurring updates centered on ECG analysis, heart rate variability analytics, remote cardiac monitoring, and cardiovascular research support.
News for AIMLF also covers activity at its Neural Cloud Solutions subsidiary, including MaxYield™, CardioYield™, and Insight 360™ commercialization, reseller and distribution agreements, research-services collaborations, medical advisory board appointments, and capital-structure actions such as private placements, convertible debentures, warrants, options, and share issuances for debt settlement.
AI/ML Innovations Inc. (CSE:AIML; OTCQB:AIMLF) has successfully closed a non-brokered private placement, raising $305,190.04 by accepting subscriptions for 5,086,498 units priced at $0.06 per unit. Each unit comprises one common share and one common share purchase warrant, allowing the purchase of an additional share at $0.10 for two years, with potential acceleration if shares trade at or above $0.20 for 10 consecutive days. A total of 420,000 units were subscribed by an insider. The funds will be used for general working capital, while the securities are subject to a hold period until July 15, 2023.
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) announced that its subsidiary, Health Gauge Inc., completed a successful blood pressure validation study for its wearable device, the Phoenix. This study indicates the device's compliance with regulatory standards for medical devices. The CTO noted the importance of finishing the FDA verification process, which would make Phoenix a Class 2 medical device approved for blood pressure monitoring. The study showcased the effectiveness of Health Gauge's AI technology, revealing minimal mean absolute errors in blood pressure estimations. This milestone supports upcoming FDA and Health Canada submissions, enhancing future business opportunities.
Summary not available.
AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) successfully closed its warrant exercise incentive program on January 19, 2023. The program encouraged the exercise of up to 5,648,000 Eligible Warrants at $0.075 per Common Share. A total of 1,845,000 warrants were exercised, generating proceeds of $138,375 for general working capital. Participants received additional Incentive Warrants allowing the purchase of one Common Share at $0.10 until January 19, 2024. The company is focused on the AI and ML sectors, particularly in digital health and wellbeing, through strategic partnerships. For more details, visit AI/ML Innovations.
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) announced a collaboration between its subsidiary, Health Gauge Inc., and TaqTik Health, Inc. to pilot an AI-enhanced remote monitoring solution for obesity patients. The pilot, involving bariatric surgeons in Mexico and Asia, aims to support lifestyle modification and weight loss for patients post-surgery. TaqTik, serving over 35,000 remote obesity patients, will leverage Health Gauge's digital health platform to enhance patient outcomes. The partnership highlights the growing global obesity crisis, with obesity rates tripling since 1975, impacting approximately one billion people by 2030.
AI/ML Innovations Inc. (CSE:AIML; OTCQB:AIMLF) announced the successful closing of its warrant exercise incentive program, encouraging the exercise of 5,648,000 unlisted common share purchase warrants. A total of 2,420,000 Eligible Warrants were exercised, resulting in proceeds of $181,500 for general working capital. Each holder also received an additional warrant, valid until January 9, 2024, for a Common Share at $0.10. The program aims to enhance liquidity and shareholder value as the company expands in the AI and digital health sectors.
AI/ML Innovations Inc. (AIMLF) has announced the launch of its subsidiary Tech2Heal SAS's Alakin ARPC Platform, a comprehensive solution for remote patient care. This 'third-generation' platform enhances patient engagement and streamlines workflows for healthcare providers, addressing limitations found in conventional monitoring systems. Alakin, which complies with HIPAA and supports FHIR standards, offers features such as telemedicine, scheduling management, and a multilingual mobile app. Its flexibility accommodates various healthcare settings, from oncology to primary care, ultimately aiming to improve patient outcomes.
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) announced on January 4, 2023, that its subsidiary, Health Gauge Inc., is considering enforcement actions regarding its patent rights for a personal health monitoring solution. The company holds US Patent No. 11183303, which covers multiple wearable health monitor configurations and methods for analyzing health metrics. Tim Daniels, Chairman, indicated potential infringement by industry participants, highlighting the significant market value of wearable health tech in the US, estimated at several billion dollars annually.
AI/ML Innovations Inc. has engaged Octagon Media Corp for a four-month marketing services agreement to support its digital media campaign. The agreement involves a payment of US$60,000, compensated through 800,000 common shares at CAD$0.10 each. Additionally, Octagon will receive options to purchase 300,000 shares at CAD$0.20. AI/ML focuses on AI and ML technologies for healthcare solutions, with investments in companies like Health Gauge and AI Rx Inc..
AI/ML Innovations Inc. has launched a warrant exercise incentive program to encourage the early exercise of up to 5,648,000 common share purchase warrants. This initiative aims to boost working capital through the exercise of Series 'B' and Series 'D' Warrants with repriced prices of $0.075 and $0.20, respectively. The early exercise period runs from December 19, 2022, to January 9, 2023. The company anticipates gross proceeds of up to $423,600 and plans to issue additional incentive warrants. The program requires approval from the Canadian Securities Exchange.